| http://purl.uniprot.org/citations/32109138 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/32109138 | http://www.w3.org/2000/01/rdf-schema#comment | "Background: Zhang et al. characterized a novel oncogenic long noncoding RNA (lncRNA) named NR2F2-AS1 in lung cancer. In this study, the role of lncRNA NR2F2-AS1 in clear cell renal cell carcinoma (ccRCC) was explored. Materials and Methods: Levels of NR2F2-AS1 and Rac1 mRNA expression in both cancer and noncancer tissues from 60 patients with ccRCC were measured by performing RT-qPCR. NR2F2-AS1 siRNA silencing and overexpression experiments were performed to analyze the role of NR2F2-AS1 in regulating Rac1 expression. Cell stemness was analyzed by stemness assay. Results: NR2F2-AS1 was upregulated in ccRCC, and high NR2F2-AS1 expression levels in ccRCC tissues were associated with poor survival. Rac1 was also upregulated in ccRCC and positively correlated with NR2F2-AS1. In ccRCC cells, NR2F2-AS1 overexpression mediated the upregulation of Rac1, whereas NR2F2-AS1 siRNA was accompanied by Rac1 downregulation. NR2F2-AS1 and Rac1 overexpression resulted in the increased ccRCC cell stemness, whereas NR2F2-AS1 and Rac1 siRNA silencing played an opposite role. Rac1 overexpression inhibited the role of NR2F2-AS1 siRNA silencing. Conclusions: NR2F2-AS1 may upregulate Rac1 to increase cancer stemness in ccRCC."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.org/dc/terms/identifier | "doi:10.1089/cbr.2019.3319"xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Chen L."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Liu F."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Tian Y."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Shen H."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Xu X."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Xiao J."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Zhang D."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/author | "Ding T."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/date | "2020"xsd:gYear |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/name | "Cancer Biother Radiopharm"xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/pages | "301-306"xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/title | "LncRNA NR2F2-AS1 Upregulates Rac1 to Increase Cancer Stemness in Clear Cell Renal Cell Carcinoma."xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://purl.uniprot.org/core/volume | "35"xsd:string |
| http://purl.uniprot.org/citations/32109138 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/32109138 |
| http://purl.uniprot.org/citations/32109138 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/32109138 |
| http://purl.uniprot.org/uniprot/#_F1D8R0-mappedCitation-32109138 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/32109138 |
| http://purl.uniprot.org/uniprot/#_P24468-mappedCitation-32109138 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/32109138 |
| http://purl.uniprot.org/uniprot/F1D8R0 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/32109138 |
| http://purl.uniprot.org/uniprot/P24468 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/32109138 |